The Supreme Court of India has informed the country’s central government that drug prices are too high and should not be raised again.

The criticism came during a Public Interest Litigation hearing, discussing the government’s newly proposed National Pharmaceuticals Pricing Policy.

The policy hopes to separate drug ceiling prices from bulk manufacturing costs, a move which critics claim would see the prices of essential drugs increase beyond the means of many people.

India’s Department of Chemicals and Petrochemicals confirmed that under the new policy, all 348 medicines on the country’s National List of Essential Medicines would come under price control instead of the 74 bulk drugs currently controlled.

The hearing was adjourned until 17 January 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.